Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: ...

Novavax (NVAX) stock jumped today following the release of the vaccine maker’s Q4 2024 earnings report. That follows its diluted earnings per ...

Novavax Inc. closed 68.94% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax (NVAX) delivered earnings and revenue surprises of 32% and 2.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Shares of Novavax Inc. NVAX advanced 2.09% to $7.32 Wednesday, on what proved to be an all-around mixed trading session for ...

Reports Q4 revenue $88.3M, consensus $84.38M. “In 2024, we unveiled our new corporate growth strategy, shifting our focus from commercializing ...

B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...